| Rheumatoid Arthritis
Naprelan vs Orencia
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Naprelan vs Orencia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOrencia has a higher rate of injection site reactions vs Naprelan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Orencia but not Naprelan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Naprelan
Orencia
At A Glance
Oral
Daily
NSAID
SC injection, IV infusion
Weekly (SC) or every 4 weeks (IV)
Selective T-cell costimulation modulator
Indications
- Rheumatoid Arthritis
- Degenerative polyarthritis
- Ankylosing spondylitis
- Tendinitis
- Bursitis
- Gout
- Primary dysmenorrhea
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Acute GVH disease
Dosing
Rheumatoid Arthritis, Degenerative polyarthritis, Ankylosing spondylitis 750 mg or 1,000 mg once daily; may be increased to 1,500 mg once daily for limited periods when a higher level of anti-inflammatory/analgesic activity is required.
Tendinitis, Bursitis, Primary dysmenorrhea 1,000 mg once daily; for patients requiring greater analgesic benefit, 1,500 mg may be used for a limited period; total daily dose should not exceed 1,000 mg thereafter.
Gout 1,000-1,500 mg once daily on the first day, followed by 1,000 mg once daily until the attack subsides.
Rheumatoid Arthritis IV: weight-based (500-1,000 mg) infused over 30 minutes at Weeks 0, 2, and 4, then every 4 weeks; SC: 125 mg once weekly, with optional IV loading dose on Day 1.
Juvenile polyarthritis IV (>=6 yrs): 10 mg/kg (body weight <75 kg) or adult weight-based dose (>=75 kg, max 1,000 mg) at Weeks 0, 2, and 4, then every 4 weeks; SC (>=2 yrs): 50 mg (10 to <25 kg), 87.5 mg (25 to <50 kg), or 125 mg (>=50 kg) once weekly without IV loading dose.
Arthritis, Psoriatic Adult IV: weight-based (500-1,000 mg) over 30 minutes at Weeks 0, 2, and 4, then every 4 weeks; Adult SC: 125 mg once weekly without IV loading dose; Pediatric SC (>=2 yrs): 50 mg (10 to <25 kg), 87.5 mg (25 to <50 kg), or 125 mg (>=50 kg) once weekly.
Acute GVH disease IV: patients >=6 yrs: 10 mg/kg (max 1,000 mg) over 60 minutes on Day -1, then Days 5, 14, and 28 post-transplant; patients 2 to <6 yrs: 15 mg/kg on Day -1, then 12 mg/kg on Days 5, 14, and 28.
Contraindications
- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
- Coronary artery bypass graft (CABG) surgery
—
Adverse Reactions
Most common (>=10%) headache, dyspepsia, flu syndrome
Serious cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity
Most common (>=10%) Headache, nasopharyngitis, upper respiratory tract infection, nausea (RA); in aGVHD: anemia, hypertension, CMV reactivation/infection, pyrexia, pneumonia, epistaxis, CD4 lymphocytes decreased, hypermagnesemia, acute kidney injury.
Serious Serious infections (pneumonia, cellulitis, urinary tract infection, bronchitis, diverticulitis), malignancies (lung cancer, lymphoma), hypersensitivity reactions, acute infusion-related reactions, COPD exacerbation.
Postmarketing Vasculitis (cutaneous and leukocytoclastic), new or worsening psoriasis, non-melanoma skin cancers (basal cell and squamous cell carcinoma), angioedema, fatal anaphylaxis (IV), systemic injection reactions (SC).
Pharmacology
Naproxen is an NSAID with analgesic, anti-inflammatory, and antipyretic properties that acts by inhibiting cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis in peripheral tissues.
Abatacept is a selective T-cell costimulation modulator that inhibits T-lymphocyte activation by binding to CD80 and CD86, thereby blocking the CD28 costimulatory interaction required for full T-cell activation; activated T lymphocytes are implicated in the pathogenesis of RA, pJIA, and PsA.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Naprelan
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (10/12)
Orencia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Naprelan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Orencia
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (5/8)
Humana
Naprelan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Orencia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Naprelan.
No savings programs available for Orencia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NaprelanView full Naprelan profile
OrenciaView full Orencia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.